Press Release: Carisma Announces Delisting From Nasdaq And Sec Deregistration

Investing.com -- Carisma Therapeutics Inc (NASDAQ:CARM) stock plummeted 41.6% in trading Friday after the company received a delisting determination from Nasdaq.

The clinical-stage biopharmaceutical company disclosed that its common stock will be suspended from trading on Nasdaq effective October 13, 2025, following previously disclosed noncompliance with Nasdaq Listing Rules. Carisma does not plan to appeal the determination.

The company has secured approval to transfer its listing to the OTCID market tier operated by The OTC Markets Group, where it expects to begin trading on October 13 under its current symbol "CARM." However, Carisma cautioned that there is no guarantee brokers will continue to make a market in its stock or that trading will continue on the OTCID market.

In a concerning development for investors, Carisma stated it will "continue to attempt to sell or otherwise dispose of or monetize its remaining assets and pursue an orderly wind down of its remaining operations." The company warned it is "unlikely that there will be a meaningful amount of cash available for distribution to stockholders" during this process.

Following the delisting, Carisma may file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Industrials, Technology and Financials sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average fell 0.55%, while the S&P 500 index fell 0.69%, and the NASDAQ Composite index lost 0.82%.

The best performers of the session on the Dow Jones Industrial Average were Merck & Company Inc (NYSE:MRK), which rose 1.62% or 1.36 points to trade at 85.48 at the close. Meanwhile, McDonald’s Corporation (NYSE:MCD) added 1.28% or 4.00 points to end at 315.77 and Boeing Co (NYSE:BA) was up 1.15% or 2.70 points to 237.38 in late trade.

The worst performers of the session were Nike Inc (NYSE:NKE), which fell 3.98% or 3.08 points to trade at 74.29 at the close. NVIDIA Corporation (NASDAQ:NVDA) declined 1.97% or 3.44 points to end at 170.78 and Goldman Sachs Group Inc (NYSE:GS) was down 1.93% or 14.40 points to 730.85.

The top performers on the S&P 500 were Ulta Beauty Inc (NASDAQ:ULTA) which rose 8.08% to 532.54, Biogen Inc (NASDAQ:BIIB) which was up 5.60% to settle at 139.63 and Ralph Lauren Corp Class A (NYSE:RL) which gained 4.75% to close at 311.02.

The worst performers were Kraft Heinz Co (NASDAQ:KHC) which was down 6.97% to 26.02 in late trade, Transdigm Group Incorporated (NYSE:TDG) which lost 6.72% to settle at 1,304.88 and Constellation Brands Inc Class A (NYSE:STZ) which was down 6.60% to 151.26 at the close.

The top performers on the NASDAQ Composite were MSP Recovery Inc (NASDAQ:MSPR) which rose 653.71% to 3.39, HWH International Inc (NASDAQ:HWH) which was up 229.81% to settle at 4.75 and Carisma Therapeutics Inc (NASDAQ:CARM) which gained 104.65% to close at 0.44.

The worst performers were Chijet Motor Co Inc (NASDAQ:CJET) which was down 66.48% to 0.59 in late trade, Next Technology Holding Inc (NASDAQ:NXTT) which lost 42.40% to settle at 0.25 and Laser Photonics Corp Unit (NASDAQ:LASE) which was down 37.19% to 2.53 at the close.

Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1915 to 854 and 73 ended unchanged; on the Nasdaq Stock Exchange, 2158 fell and 1186 advanced, while 126 ended unchanged.

Shares in Ralph Lauren Corp Class A (NYSE:RL) rose to all time highs; up 4.75% or 14.09 to 311.02. Shares in Constellation Brands Inc Class A (NYSE:STZ) fell to 5-year lows; down 6.60% or 10.68 to 151.26. Shares in Boeing Co (NYSE:BA) rose to 52-week highs; rising 1.15% or 2.70 to 237.38. Shares in Chijet Motor Co Inc (NASDAQ:CJET) fell to all time lows; down 66.48% or 1.17 to 0.59.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was up 6.76% to 17.21.

Gold Futures for December delivery was up 2.42% or 85.05 to $3,601.15 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in October rose 2.44% or 1.56 to hit $65.57 a barrel, while the November Brent oil contract rose 1.36% or 0.93 to trade at $69.08 a barrel.

EUR/USD was down 0.59% to 1.16, while USD/JPY rose 0.80% to 148.38.

The US Dollar Index Futures was up 0.59% at 98.27.

Investing.com -- Carisma Therapeutics Inc (NASDAQ:CARM) stock surged 107% following news of its merger agreement with Ocugen Inc (NASDAQ:OCGN) and a related private placement investment.

The company has entered into an agreement where Azalea Merger Sub, a wholly owned subsidiary of Carisma, will merge with OrthoCellix, a wholly owned subsidiary of Ocugen. Under the terms announced, OrthoCellix will continue as a wholly owned subsidiary of Carisma and the surviving company of the merger.

As part of the deal, Carisma entered into a subscription agreement with Ocugen on August 29, 2025, for a private placement investment of $5 million in Carisma common stock. This investment is part of a larger anticipated concurrent investment expected to raise at least $25 million in aggregate gross proceeds.

The price per share for the Ocugen investment will be calculated by dividing the aggregate valuation by the post-closing parent shares, as defined in the merger agreement. The transaction is subject to approval by Carisma’s stockholders under Nasdaq rules and other customary closing conditions.

Chardan Capital Markets LLC and Lake Street Capital Markets, LLC are serving as placement agents for the Ocugen investment. The companies also plan to enter into a registration rights agreement for the resale of certain shares of common stock held by investors participating in the concurrent investment.

The merger and related investments represent a significant development for Carisma, as reflected in today’s substantial stock price movement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.